

Legislation Text

File #: 22-00659, Version: 1

Consider recommendations regarding Behavioral Wellness Alcohol and Drug Program - Request for Waiver of Competition in Purchasing of Pharmaceuticals from Emergent Devices Inc. for Fiscal Years (FYs) 2022-2025, as follows:

a) Authorize the Purchasing Agent to procure Narcan/naloxone nasal spray for harm reductions to treat opioid overdose from Emergent Devices Inc. dba Emergent BioSolutions (Emergent) (not a local vendor) without being required to conduct a formal bid process, with a Maximum Agreement Amount not to exceed \$180,000.00 with an annual amount of \$60,000.00 for the period of July 1, 2022 through June 30, 2025; and

b) Determine that the above action is a government fiscal activity or funding mechanisms which does not involve any commitment to any specific project which may result in a potentially significant physical impact on the environment, and is therefore not a project under the California Environmental Quality Act (CEQA) pursuant to section 15378(b)(4) of the CEQA Guidelines.